Q-omics provides the consensus-scored GNA14 profile across patient tissues and cancer cell-line models. GNA14 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GNA14 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GNA14 RNA expression shows 19,966 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where GNA14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNA14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNA14 survival associations across molecular data types. GNA14 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNA14 RNA expression–survival associations across cancer types. High GNA14 expression shows unfavorable associations in KIRP and UVM, but favorable associations in KIRC, LIHC, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GNA14 RNA expression.
This table summarizes GNA14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GNA14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNA14 shows lower tumor expression in KIRC, KIRP, KICH, THCA, LUSC and HNSC. The KIRC box plot shows higher GNA14 RNA expression in normal versus tumor tissue (log2 FC = −0.933, t-test p < 0.001).
This table shows molecular features associated with GNA14 in patient tissues and cancer cell lines. In patient samples, GNA14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNA14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
